Mercer Global Advisors
MCRB icon

Mercer Global Advisors’s Seres Therapeutics MCRB Stock Holding History

Mercer Global Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$292 Buy
+37
New +$282 ﹤0.01% 5890

Other funds holding MCRB

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mercer Global Advisors's MCRB Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Seres Therapeutics (MCRB) in Q2 2026: 37 shares worth $292. The stake represents ﹤0.01% of the portfolio and ranks #5890 among its holdings.

22 funds tracked by Wall St. Rank hold MCRB as of Q2 2026.

  • Mercer Global Advisors held 37 shares of Seres Therapeutics worth $292 as of Q2 2026.
  • Seres Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • Seres Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5890 holding.
  • 22 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.